In this article
Key takeaways
- Success rates claimed by rehab programmes are not comparable because there is no standard definition, measurement period, or follow-up protocol.
- Research shows that 40-60% of people maintain abstinence at 12-month follow-up after alcohol use disorder treatment, with outcomes improving significantly with continuing care.
- Treatment duration of 90 days or longer consistently outperforms 28-day programmes on long-term abstinence measures according to NIDA treatment principles.
- Relapse rates for addiction (40-60% within first year) are comparable to chronic diseases like hypertension and diabetes - relapse is a clinical event, not treatment failure.
- The chronic disease model frames treatment success as sustained recovery management and improved functioning, not as a one-time cure.
The problem with success rate claims
Any website advertising a rehabilitation programme will make claims about success. "90% of our clients achieve lasting sobriety." "Our outcomes exceed the national average." These figures are everywhere - and almost none of them are comparable, verifiable, or defined consistently.
The problem is not that these programmes are necessarily lying. It is that "success" in addiction treatment has no agreed-upon definition, no standardised measurement period, and no universal follow-up protocol. A programme that defines success as "completed the 28-day programme" and a programme that defines it as "abstinent at five-year follow-up" will report wildly different numbers - and both can claim their statistic accurately.
Before evaluating any claim about success rates, the first question to ask is always: success as defined by whom, measured when, and in what population?
How research defines success
Peer-reviewed addiction research typically uses several outcome measures. Abstinence - complete cessation of substance use - is the most common, but increasingly researchers also track reduction in use, reduction in harm, quality of life indicators, social functioning, and treatment re-engagement following relapse.
Is this something you're dealing with?
Free confidential advice - no pressure, no obligation.
The National Institute on Drug Abuse (NIDA) in the United States frames addiction treatment outcomes similarly to other chronic disease management: not cure, but sustained management, reduced harm, and improved functioning. This is a fundamentally different framework from "did the person stop using."
Measurement timing matters enormously. Studies that follow up at 30 days post-treatment will report higher abstinence rates than those following up at 12 months. The most rigorous studies use 12-month follow-up as a minimum, and some track outcomes over five years or more.
What the evidence shows
The most consistent finding across decades of addiction treatment research is that treatment works - significantly better than no treatment, and significantly better than attempts at unassisted abstinence for most people with moderate to severe dependence.
A 2020 review in JAMA Psychiatry found that among people who received structured residential treatment for alcohol use disorder, approximately 40 to 60 percent maintained abstinence at 12-month follow-up. For those who received comprehensive continuing care (structured aftercare, ongoing therapy, and peer support), outcomes improved significantly - suggesting that what happens after the residential period is at least as important as the residential period itself.
For opioid use disorder, the evidence consistently supports medication-assisted treatment (MAT) combined with psychosocial support. Studies of buprenorphine and methadone maintenance, combined with counselling, show retention rates and abstinence outcomes substantially better than abstinence-only residential programmes alone. This is worth knowing when evaluating programmes: a residential programme that does not engage with MAT where clinically appropriate is not following best-practice guidelines for opioid dependence.
For stimulant addiction (cocaine, methamphetamine), the evidence base is weighted more heavily toward psychosocial interventions - particularly cognitive behavioural therapy and contingency management - as there are currently no approved pharmacological treatments in this category. Residential outcomes here are more variable and more dependent on programme quality and post-treatment support.
Factors that predict better outcomes
Research has identified several factors that consistently predict better treatment outcomes, regardless of substance:
- Longer treatment duration. Programmes of 90 days or longer consistently outperform 28-day programmes on long-term abstinence measures. The NIDA treatment principles reflect this: for most people with significant dependence, 28 days is a starting point, not a complete treatment course.
- Quality and frequency of individual therapy. Programmes with higher ratios of one-to-one clinical contact - rather than predominantly group-based content - show better outcomes.
- Comprehensive assessment and dual diagnosis treatment. Approximately 50 percent of people with addiction also have a co-occurring mental health condition. Programmes that treat both concurrently produce better outcomes than those treating addiction alone.
- Structured aftercare and continuing care. Post-residential support - whether through outpatient therapy, peer support groups, or sober living - is one of the strongest predictors of maintained recovery.
- Family involvement. Research consistently shows that involving family members in treatment improves outcomes, particularly for younger clients and those whose primary relationships are central to their recovery environment.
Why relapse does not mean failure
The most important reframe in understanding treatment success is understanding what relapse means - and does not mean.
Relapse rates for addiction (variously estimated at 40 to 60 percent within the first year post-treatment) are frequently cited as evidence that treatment does not work. The comparison that dismantles this argument is to other chronic conditions. Relapse rates for hypertension, type 2 diabetes, and asthma are in the same range - yet no one argues that blood pressure medication does not work because some patients' numbers go up again when they stop taking it.
Relapse is a clinical event, not a moral failure, and it is part of the recovery process for many people. The evidence is clear that people who relapse and re-engage with treatment - rather than withdrawing from the treatment system entirely - have outcomes comparable to those who maintain uninterrupted abstinence.
See also: Relapse Is Not Failure - Understanding the Recovery Cycle
The chronic disease model
The most evidence-consistent framework for understanding addiction and its treatment is the chronic disease model, formalised by McLellan et al. in a landmark 2000 paper in JAMA. This paper demonstrated that addiction shares aetiology, heritability, brain changes, and relapse profiles with chronic conditions such as hypertension and asthma - and that treating it as an acute condition requiring a single episode of intensive care is fundamentally misaligned with the neuroscience.
Under the chronic disease model, the goal of residential treatment is not cure but stabilisation, skills development, and the initiation of a longer recovery process. Success is not "left treatment and never used again" but "entered and sustained a recovery trajectory" - which may include bumps, re-engagements with treatment, and ongoing professional support.
This model is not pessimistic. It is more hopeful than the binary success/failure framing, because it removes the catastrophising that occurs when a relapse is treated as proof that recovery is impossible.
What this means when choosing a programme
When evaluating a residential programme, the right questions to ask about outcomes are not "what is your success rate" but rather:
- How do you define and measure outcomes, and over what time period?
- What does your post-treatment continuing care look like?
- Do you treat co-occurring mental health conditions within the programme?
- What is the ratio of individual therapy to group content?
- What is the clinical background of your therapists?
A programme that answers these questions with specificity and honesty is more likely to be a quality programme than one that leads with a headline success percentage and no further detail.
The honest expectation
For someone entering a quality residential programme with good aftercare support, the realistic expectation is this: a structured period of physiological stabilisation, meaningful therapeutic work, and the development of recovery skills and insight - followed by a transition to ongoing support that substantially improves the probability of long-term recovery.
That is not a guarantee. No ethical clinician will offer one. But it is also not the bleak picture that treatment sceptics sometimes paint. The evidence strongly supports residential treatment as effective - not as a one-time fix, but as the beginning of a managed, supported recovery process that works for the majority of people who engage with it seriously.
Questions about the treatment process?
Free confidential advice. We can help you understand what to expect and what questions to ask.
Sources
- National Institute on Drug Abuse (NIDA). Principles of Drug Addiction Treatment - A Research-Based Guide. U.S. Department of Health and Human Services.
- McLellan, A.T., Lewis, D.C., O'Brien, C.P., & Kleber, H.D. 2000. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA, 284(13), 1689-1695.
- Substance Abuse and Mental Health Services Administration (SAMHSA). National Helpline - Free and Confidential Treatment Referral and Information Service. U.S. Department of Health and Human Services.